RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oncolys Biopharma

Oncolys Biopharma Market capitalization 2024

Oncolys Biopharma Market capitalization

12.14 B JPY

Oncolys Biopharma Dividend yield

Ticker

4588.T

ISIN

JP3202170001

WKN

A1W94N

In 2024, Oncolys Biopharma's market cap stood at 12.14 B JPY, a 0.56% increase from the 12.07 B JPY market cap in the previous year.

The Oncolys Biopharma Market capitalization history

YEARREVENUE (undefined JPY)GROSS MARGIN (%)NET INCOME (undefined JPY)
2026e3.30,93-999.42
2025e1.821,68-694.18
2024e1.013,03-486.98
20230.0648,55-1,938.51
20220.9834,67-1,148.94
20210.6430,94-1,615.44
20200.3175,15-2,095.09
20191.391,34-912.35
20180.1728,01-1,233.85
20170.2368,77-1,090.7
20160.1899,99-931.4
20150.1299,99-857.29
20140.0398,61-739
2013091,67-635.6
20120.4100,00-102.8
20110.1997,9044.9
20100.2799,1737.5
20090.0759,05-906.8
20080.2595,68-1,615.1

Oncolys Biopharma Aktienanalyse

What does Oncolys Biopharma do?

Oncolys Biopharma Inc. is a company specialized in the development of innovative medications for the treatment of cancer. The company was founded in 2001 in Tokyo, Japan and has become a key player in the biotechnology industry over the years. The company's business model is based on the development of innovative therapies for cancer patients. It works closely with leading scientists and researchers to advance its research projects, focusing on the discovery and development of new compounds based on the OncoTherad virus. Oncolys Biopharma Inc. offers a wide range of products and services, including cancer medications based on the OncoTherad virus, as well as diagnostic and monitoring tools for hospitals and medical facilities. It has various divisions that encompass research and development, manufacturing, and distribution and marketing of cancer medications and diagnostic systems. The company is committed to expanding its research and development activities to develop new medications for different types of cancer. In addition to cancer medications, Oncolys Biopharma Inc. is also working on developing therapies for other serious illnesses such as viral diseases. The company has a promising pipeline of new medications being tested in various clinical trials. Overall, Oncolys Biopharma Inc. is a key player in the biotechnology industry specializing in the development of innovative therapies for cancer and viral diseases. The company has built an excellent reputation over the years and is committed to continuing its growth and expansion. Oncolys Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Oncolys Biopharma's Market Capitalization

Oncolys Biopharma's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Oncolys Biopharma's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Oncolys Biopharma's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Oncolys Biopharma’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Oncolys Biopharma Stock

What is the current Oncolys Biopharma market capitalization?

The current market capitalization of Oncolys Biopharma is 12.14 B JPY.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Oncolys Biopharma.

How has the market capitalization of Oncolys Biopharma developed in recent years?

The market capitalization of Oncolys Biopharma has increased/decreased by 0.56% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Oncolys Biopharma?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Oncolys Biopharma?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Oncolys Biopharma have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Oncolys Biopharma pay?

Over the past 12 months, Oncolys Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncolys Biopharma is expected to pay a dividend of 0 JPY.

What is the dividend yield of Oncolys Biopharma?

The current dividend yield of Oncolys Biopharma is .

When does Oncolys Biopharma pay dividends?

Oncolys Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncolys Biopharma?

Oncolys Biopharma paid dividends every year for the past 0 years.

What is the dividend of Oncolys Biopharma?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncolys Biopharma located?

Oncolys Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncolys Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncolys Biopharma from 6/5/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 6/5/2024.

When did Oncolys Biopharma pay the last dividend?

The last dividend was paid out on 6/5/2024.

What was the dividend of Oncolys Biopharma in the year 2023?

In the year 2023, Oncolys Biopharma distributed 0 JPY as dividends.

In which currency does Oncolys Biopharma pay out the dividend?

The dividends of Oncolys Biopharma are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oncolys Biopharma

Our stock analysis for Oncolys Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncolys Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.